Esperion Therapeutics | ESPR - Interest Expense On Debt

Stock Price
3.49
Daily Change
0.10 2.80%
Monthly
-1.83%
Yearly
85.37%
Q1 Forecast
2.70

Esperion Therapeutics reported $15.08M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amarin USD 3K 5K Dec/2024
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Cipla INR 140.3M 8.5M Dec/2025
CSL USD 104M 136M Jun/2025
Cytokinetics USD 26.32M 2.06M Sep/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
Geron USD 8.64M 128K Sep/2025
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 4.3M 98K Sep/2025
Heron Therapeutics USD 500K 900K Sep/2024
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Merck USD 412M 85M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 12.14B 12.13B Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
United Therapeutics USD 3M 4.3M Sep/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025